N/A
Manufactured by SEVENE USA
9 FDA adverse event reports analyzed
Last updated: 2026-04-15
LYTTA VESICATORIA is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by SEVENE USA. The most commonly reported adverse reactions for LYTTA VESICATORIA include ABDOMINAL PAIN UPPER, DEVICE RELATED INFECTION, DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS, GASTRIC DISORDER, HEPATIC FUNCTION ABNORMAL. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for LYTTA VESICATORIA.
Out of 3 classified reports for LYTTA VESICATORIA:
The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.
Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.
This profile reflects 9 FDA FAERS reports that mention LYTTA VESICATORIA. Reporting is voluntary and does not prove that the drug caused any listed event.
Frequently reported terms in FAERS include ABDOMINAL PAIN UPPER, DEVICE RELATED INFECTION, DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS, GASTRIC DISORDER, HEPATIC FUNCTION ABNORMAL, MALAISE. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.
Labeling and FAERS entries often list SEVENE USA in connection with LYTTA VESICATORIA. Always verify the specific product and NDC with your pharmacist.